Glycoursodeoxycholic Acid-d₄

MedChemExpress

R

Cat. No.:	HY-N1424S			
CAS No.:	2044276-17-5			
Molecular Formula:	C ₂₆ H ₃₉ D ₄ NO ₅			
Molecular Weight:	453.65			
Target:	Endogenous Metabolite			
Pathway:	Metabolic Enzyme/Protease			
Storage:	Powder	-20°C	3 years	
	In solvent	-80°C	6 months	
		-20°C	1 month	

SOLVENT & SOLUBILITY

Preparing Stock Solutions	Mass Solvent Concentration	1 mg	5 mg	10 mg
	1 mM	2.2043 mL	11.0217 mL	22.0434 mL
	5 mM	0.4409 mL	2.2043 mL	4.4087 mL
	10 mM	0.2204 mL	1.1022 mL	2.2043 mL
Please refer to the so	lubility information to select the ap	propriate solvent.		
	· ·	G300 >> 5% Tween-80) >> 45% saline	
		% SBE-β-CD in saline)		
3. Add each solvent	one by one: 10% DMSO >> 90% cor	n oil		
	 Stock Solutions Please refer to the so 1. Add each solvent Solubility: ≥ 1.25 r 2. Add each solvent Solubility: ≥ 1.25 r 	Preparing 1 mM Stock Solutions 5 mM 10 mM 10 mM Please refer to the solubility information to select the application in the solubility information to select the application in the solubility: ≥ 1.25 mg/mL (2.76 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20 Solubility: ≥ 1.25 mg/mL (2.76 mM); Clear solution	Solvent 1 mg Preparing 1 mM 2.2043 mL Stock Solutions 5 mM 0.4409 mL 10 mM 0.2204 mL Please refer to the solubility information to select the appropriate solvent. 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 Solubility: ≥ 1.25 mg/mL (2.76 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)	Solvent Concentration1 mg5 mgPreparing Stock Solutions1 mM2.2043 mL11.0217 mL5 mM0.4409 mL2.2043 mL10 mM0.2204 mL1.1022 mLPlease refer to the solubility information to select the appropriate solvent.1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (2.76 mM); Clear solution2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25 mg/mL (2.76 mM); Clear solution

BIOLOGICAL ACTIVITY				
Description	Glycoursodeoxycholic acid-d4 (Ursodeoxycholylglycine-d4) is the deuterium labeled Glycoursodeoxycholic acid. Glycoursodeoxycholic acid, a acyl glycine and a bile acid-glycine conjugate, is a metabolite of ursodeoxycholic acid[1][2].			
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

Q

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Vaz AR, et al. Bilirubin selectively inhibits cytochrome c oxidase activity and induces apoptosis in immature cortical neurons: assessment of the protective effects of glycoursodeoxycholic acid. J Neurochem. 2010 Jan;112(1):56-65.

[3]. Vaz AR, et al. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration.

[4]. Palmela I, et al. Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study. Front Neurosci. 2015 Mar 13;9:80.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA